1
|
Kudo G, Hirao T, Yoshino R, Shigeta Y, Hirokawa T. Site Identification and Next Choice Protocol for Hit-to-Lead Optimization. J Chem Inf Model 2024; 64:4475-4484. [PMID: 38768949 PMCID: PMC11167593 DOI: 10.1021/acs.jcim.3c02036] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/20/2023] [Revised: 04/11/2024] [Accepted: 04/11/2024] [Indexed: 05/22/2024]
Abstract
Time efficiency and cost savings are major challenges in drug discovery and development. In this process, the hit-to-lead stage is expected to improve efficiency because it primarily exploits the trial-and-error approach of medicinal chemists. This study proposes a site identification and next choice (SINCHO) protocol to improve the hit-to-lead efficiency. This protocol selects an anchor atom and growth site pair, which is desirable for a hit-to-lead strategy starting from a 3D complex structure. We developed and fine-tuned the protocol using a training data set and assessed it using a test data set of the preceding hit-to-lead strategy. The protocol was tested for experimentally determined structures and molecular dynamics (MD) ensembles. The protocol had a high prediction accuracy for applying MD ensembles, owing to the consideration of protein flexibility. The SINCHO protocol enables medicinal chemists to visualize and modify functional groups in a hit-to-lead manner.
Collapse
Affiliation(s)
- Genki Kudo
- Physics
Department, Graduate School of Pure and Applied Sciences, University of Tsukuba, 1-1-1 Tennodai, Tsukuba, Ibaraki 305-8571, Japan
| | - Takumi Hirao
- Doctoral
Program in Medical Sciences, Graduate School of Comprehensive Human
Sciences, University of Tsukuba, Tsukuba, Ibaraki 305-8575, Japan
- Division
of Biomedical Science, Faculty of Medicine, University of Tsukuba, 1-1-1 Tennodai, Tsukuba, Ibaraki 305-8575, Japan
| | - Ryunosuke Yoshino
- Division
of Biomedical Science, Faculty of Medicine, University of Tsukuba, 1-1-1 Tennodai, Tsukuba, Ibaraki 305-8575, Japan
- Transborder
Medical Research Center, University of Tsukuba, 1-1-1 Tennodai, Tsukuba, Ibaraki 305-8575, Japan
| | - Yasuteru Shigeta
- Center
for Computational Sciences, University of
Tsukuba, 1-1-1 Tennodai, Tsukuba, Ibaraki 305-8577, Japan
| | - Takatsugu Hirokawa
- Division
of Biomedical Science, Faculty of Medicine, University of Tsukuba, 1-1-1 Tennodai, Tsukuba, Ibaraki 305-8575, Japan
- Transborder
Medical Research Center, University of Tsukuba, 1-1-1 Tennodai, Tsukuba, Ibaraki 305-8575, Japan
| |
Collapse
|
2
|
Dichiara M, Cosentino G, Giordano G, Pasquinucci L, Marrazzo A, Costanzo G, Amata E. Designing drugs optimized for both blood-brain barrier permeation and intra-cerebral partition. Expert Opin Drug Discov 2024; 19:317-329. [PMID: 38145409 DOI: 10.1080/17460441.2023.2294118] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/08/2023] [Accepted: 12/07/2023] [Indexed: 12/26/2023]
Abstract
INTRODUCTION With the increasing incidence and prevalence of neurological disorders globally, there is a paramount need for new pharmacotherapies. BBB effectively protects the brain but raises a profound challenge to drug permeation, with less than 2% of most drugs reaching the CNS. AREAS COVERED This article reviews aspects of the most recent design strategies, providing insights into ideas and concepts in CNS drug discovery. An overview of the products available on the market is given and why clinical trials are continuously failing is discussed. EXPERT OPINION Among the available CNS drugs, small molecules account for most successful CNS therapeutics due to their ability to penetrate the BBB through passive or carrier-mediated mechanisms. The development of new CNS drugs is very difficult. To date, there is a lack of effective drugs for alleviating or even reversing the progression of brain diseases. Particularly, the use of artificial intelligence strategies, together with more appropriate animal models, may enable the design of molecules with appropriate permeation, to elicit a biological response from the neurotherapeutic target.
Collapse
Affiliation(s)
- Maria Dichiara
- Dipartimento di Scienze del Farmaco e della Salute, Università degli Studi di Catania, Catania, Italy
| | - Giuseppe Cosentino
- Dipartimento di Scienze del Farmaco e della Salute, Università degli Studi di Catania, Catania, Italy
| | - Giorgia Giordano
- Dipartimento di Scienze del Farmaco e della Salute, Università degli Studi di Catania, Catania, Italy
| | - Lorella Pasquinucci
- Dipartimento di Scienze del Farmaco e della Salute, Università degli Studi di Catania, Catania, Italy
| | - Agostino Marrazzo
- Dipartimento di Scienze del Farmaco e della Salute, Università degli Studi di Catania, Catania, Italy
| | - Giuliana Costanzo
- Dipartimento di Scienze del Farmaco e della Salute, Università degli Studi di Catania, Catania, Italy
| | - Emanuele Amata
- Dipartimento di Scienze del Farmaco e della Salute, Università degli Studi di Catania, Catania, Italy
| |
Collapse
|
3
|
Zheng Y, van den Kerkhof M, van der Meer T, Gul S, Kuzikov M, Ellinger B, de Esch IJP, Siderius M, Matheeussen A, Maes L, Sterk GJ, Caljon G, Leurs R. Discovery of 5-Phenylpyrazolopyrimidinone Analogs as Potent Antitrypanosomal Agents with In Vivo Efficacy. J Med Chem 2023; 66:10252-10264. [PMID: 37471520 PMCID: PMC10424178 DOI: 10.1021/acs.jmedchem.3c00161] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/28/2023] [Indexed: 07/22/2023]
Abstract
Human African Trypanosomiasis (HAT), caused by Trypanosoma brucei, is one of the neglected tropical diseases with a continuing need for new medication. We here describe the discovery of 5-phenylpyrazolopyrimidinone analogs as a novel series of phenotypic antitrypanosomal agents. The most potent compound, 30 (NPD-2975), has an in vitro IC50 of 70 nM against T. b. brucei with no apparent toxicity against human MRC-5 lung fibroblasts. Showing good physicochemical properties, low toxicity potential, acceptable metabolic stability, and other pharmacokinetic features, 30 was further evaluated in an acute mouse model of T. b. brucei infection. After oral dosing at 50 mg/kg twice per day for five consecutive days, all infected mice were cured. Given its good drug-like properties and high in vivo antitrypanosomal potential, the 5-phenylpyrazolopyrimidinone analog 30 represents a promising lead for future drug development to treat HAT.
Collapse
Affiliation(s)
- Yang Zheng
- Amsterdam
Institute for Molecules, Medicines and Systems, Division of Medicinal
Chemistry, Faculty of Science, Vrije Universiteit
Amsterdam, De Boelelaan 1108, 1081 HZ Amsterdam, The Netherlands
| | - Magali van den Kerkhof
- Laboratory
of Microbiology, Parasitology and Hygiene (LMPH), University of Antwerp, Universiteitsplein 1, 2610 Wilrijk, Belgium
| | - Tiffany van der Meer
- Amsterdam
Institute for Molecules, Medicines and Systems, Division of Medicinal
Chemistry, Faculty of Science, Vrije Universiteit
Amsterdam, De Boelelaan 1108, 1081 HZ Amsterdam, The Netherlands
| | - Sheraz Gul
- Fraunhofer
Institute for Translational Medicine and Pharmacology ITMP, 22525 Hamburg, Germany
- Fraunhofer
Cluster of Excellence for Immune-Mediated Diseases CIMD, 22525 Hamburg, Germany
| | - Maria Kuzikov
- Fraunhofer
Institute for Translational Medicine and Pharmacology ITMP, 22525 Hamburg, Germany
- Fraunhofer
Cluster of Excellence for Immune-Mediated Diseases CIMD, 22525 Hamburg, Germany
| | - Bernhard Ellinger
- Fraunhofer
Institute for Translational Medicine and Pharmacology ITMP, 22525 Hamburg, Germany
- Fraunhofer
Cluster of Excellence for Immune-Mediated Diseases CIMD, 22525 Hamburg, Germany
| | - Iwan J. P. de Esch
- Amsterdam
Institute for Molecules, Medicines and Systems, Division of Medicinal
Chemistry, Faculty of Science, Vrije Universiteit
Amsterdam, De Boelelaan 1108, 1081 HZ Amsterdam, The Netherlands
| | - Marco Siderius
- Amsterdam
Institute for Molecules, Medicines and Systems, Division of Medicinal
Chemistry, Faculty of Science, Vrije Universiteit
Amsterdam, De Boelelaan 1108, 1081 HZ Amsterdam, The Netherlands
| | - An Matheeussen
- Laboratory
of Microbiology, Parasitology and Hygiene (LMPH), University of Antwerp, Universiteitsplein 1, 2610 Wilrijk, Belgium
| | - Louis Maes
- Laboratory
of Microbiology, Parasitology and Hygiene (LMPH), University of Antwerp, Universiteitsplein 1, 2610 Wilrijk, Belgium
| | - Geert Jan Sterk
- Amsterdam
Institute for Molecules, Medicines and Systems, Division of Medicinal
Chemistry, Faculty of Science, Vrije Universiteit
Amsterdam, De Boelelaan 1108, 1081 HZ Amsterdam, The Netherlands
| | - Guy Caljon
- Laboratory
of Microbiology, Parasitology and Hygiene (LMPH), University of Antwerp, Universiteitsplein 1, 2610 Wilrijk, Belgium
| | - Rob Leurs
- Amsterdam
Institute for Molecules, Medicines and Systems, Division of Medicinal
Chemistry, Faculty of Science, Vrije Universiteit
Amsterdam, De Boelelaan 1108, 1081 HZ Amsterdam, The Netherlands
| |
Collapse
|
4
|
Ferrins L, Buskes MJ, Kapteyn MM, Engels HN, Enos SE, Lu C, Klug DM, Singh B, Quotadamo A, Bachovchin K, Tear WF, Spaulding AE, Forbes KC, Bag S, Rivers M, LeBlanc C, Burchfield E, Armand JR, Diaz-Gonzalez R, Ceballos-Perez G, García-Hernández R, Pérez-Moreno G, Bosch-Navarrete C, Gómez-Liñán C, Ruiz-Pérez LM, Gamarro F, González-Pacanowska D, Navarro M, Mensa-Wilmot K, Pollastri MP, Kyle DE, Rice CA. Identification of novel anti-amoebic pharmacophores from kinase inhibitor chemotypes. Front Microbiol 2023; 14:1149145. [PMID: 37234530 PMCID: PMC10206040 DOI: 10.3389/fmicb.2023.1149145] [Citation(s) in RCA: 2] [Impact Index Per Article: 2.0] [Reference Citation Analysis] [Abstract] [Key Words] [Grants] [Track Full Text] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/21/2023] [Accepted: 03/29/2023] [Indexed: 05/28/2023] Open
Abstract
Acanthamoeba species, Naegleria fowleri, and Balamuthia mandrillaris are opportunistic pathogens that cause a range of brain, skin, eye, and disseminated diseases in humans and animals. These pathogenic free-living amoebae (pFLA) are commonly misdiagnosed and have sub-optimal treatment regimens which contribute to the extremely high mortality rates (>90%) when they infect the central nervous system. To address the unmet medical need for effective therapeutics, we screened kinase inhibitor chemotypes against three pFLA using phenotypic drug assays involving CellTiter-Glo 2.0. Herein, we report the activity of the compounds against the trophozoite stage of each of the three amoebae, ranging from nanomolar to low micromolar potency. The most potent compounds that were identified from this screening effort were: 2d (A. castellanii EC50: 0.92 ± 0.3 μM; and N. fowleri EC50: 0.43 ± 0.13 μM), 1c and 2b (N. fowleri EC50s: <0.63 μM, and 0.3 ± 0.21 μM), and 4b and 7b (B. mandrillaris EC50s: 1.0 ± 0.12 μM, and 1.4 ± 0.17 μM, respectively). With several of these pharmacophores already possessing blood-brain barrier (BBB) permeability properties, or are predicted to penetrate the BBB, these hits present novel starting points for optimization as future treatments for pFLA-caused diseases.
Collapse
Affiliation(s)
- Lori Ferrins
- Department of Chemistry and Chemical Biology, Northeastern University, Boston, MA, United States
| | - Melissa J. Buskes
- Department of Chemistry and Chemical Biology, Northeastern University, Boston, MA, United States
| | - Madison M. Kapteyn
- Center for Tropical and Emerging Global Diseases, University of Georgia, Athens, GA, United States
| | - Hannah N. Engels
- Center for Tropical and Emerging Global Diseases, University of Georgia, Athens, GA, United States
| | - Suzanne E. Enos
- Center for Tropical and Emerging Global Diseases, University of Georgia, Athens, GA, United States
- Department of Pharmaceutical and Biomedical Sciences, College of Pharmacy, University of Georgia, Athens, GA, United States
| | - Chenyang Lu
- Department of Comparative Pathobiology, College of Veterinary Medicine, Purdue University, West Lafayette, IN, United States
| | - Dana M. Klug
- Department of Chemistry and Chemical Biology, Northeastern University, Boston, MA, United States
| | - Baljinder Singh
- Department of Chemistry and Chemical Biology, Northeastern University, Boston, MA, United States
| | - Antonio Quotadamo
- Department of Chemistry and Chemical Biology, Northeastern University, Boston, MA, United States
- Clinical and Experimental Medicine PhD Program, University of Modena and Reggio Emilia, Modena, Italy
| | - Kelly Bachovchin
- Department of Chemistry and Chemical Biology, Northeastern University, Boston, MA, United States
| | - Westley F. Tear
- Department of Chemistry and Chemical Biology, Northeastern University, Boston, MA, United States
| | - Andrew E. Spaulding
- Department of Chemistry and Chemical Biology, Northeastern University, Boston, MA, United States
| | - Katherine C. Forbes
- Department of Chemistry and Chemical Biology, Northeastern University, Boston, MA, United States
| | - Seema Bag
- Department of Chemistry and Chemical Biology, Northeastern University, Boston, MA, United States
| | - Mitch Rivers
- Department of Chemistry and Chemical Biology, Northeastern University, Boston, MA, United States
| | - Catherine LeBlanc
- Department of Chemistry and Chemical Biology, Northeastern University, Boston, MA, United States
| | - Erin Burchfield
- Department of Chemistry and Chemical Biology, Northeastern University, Boston, MA, United States
| | - Jeremy R. Armand
- Department of Chemistry and Chemical Biology, Northeastern University, Boston, MA, United States
| | - Rosario Diaz-Gonzalez
- Instituto de Parasitología y Biomedicina “López-Neyra” Consejo Superior de Investigaciones Científicas (CSIC), Granada, Spain
| | - Gloria Ceballos-Perez
- Instituto de Parasitología y Biomedicina “López-Neyra” Consejo Superior de Investigaciones Científicas (CSIC), Granada, Spain
| | - Raquel García-Hernández
- Instituto de Parasitología y Biomedicina “López-Neyra” Consejo Superior de Investigaciones Científicas (CSIC), Granada, Spain
| | - Guiomar Pérez-Moreno
- Instituto de Parasitología y Biomedicina “López-Neyra” Consejo Superior de Investigaciones Científicas (CSIC), Granada, Spain
| | - Cristina Bosch-Navarrete
- Instituto de Parasitología y Biomedicina “López-Neyra” Consejo Superior de Investigaciones Científicas (CSIC), Granada, Spain
| | - Claudia Gómez-Liñán
- Instituto de Parasitología y Biomedicina “López-Neyra” Consejo Superior de Investigaciones Científicas (CSIC), Granada, Spain
| | - Luis Miguel Ruiz-Pérez
- Instituto de Parasitología y Biomedicina “López-Neyra” Consejo Superior de Investigaciones Científicas (CSIC), Granada, Spain
| | - Francisco Gamarro
- Instituto de Parasitología y Biomedicina “López-Neyra” Consejo Superior de Investigaciones Científicas (CSIC), Granada, Spain
| | - Dolores González-Pacanowska
- Instituto de Parasitología y Biomedicina “López-Neyra” Consejo Superior de Investigaciones Científicas (CSIC), Granada, Spain
| | - Miguel Navarro
- Instituto de Parasitología y Biomedicina “López-Neyra” Consejo Superior de Investigaciones Científicas (CSIC), Granada, Spain
| | - Kojo Mensa-Wilmot
- Department of Molecular and Cellular Biology, Kennesaw State University, Kennesaw, GA, United States
| | - Michael P. Pollastri
- Department of Chemistry and Chemical Biology, Northeastern University, Boston, MA, United States
| | - Dennis E. Kyle
- Center for Tropical and Emerging Global Diseases, University of Georgia, Athens, GA, United States
| | - Christopher A. Rice
- Center for Tropical and Emerging Global Diseases, University of Georgia, Athens, GA, United States
- Department of Pharmaceutical and Biomedical Sciences, College of Pharmacy, University of Georgia, Athens, GA, United States
- Department of Comparative Pathobiology, College of Veterinary Medicine, Purdue University, West Lafayette, IN, United States
| |
Collapse
|
5
|
Dean DA, Haffner JJ, Katemauswa M, McCall LI. Chemical Cartography Approaches to Study Trypanosomatid Infection. J Vis Exp 2022:10.3791/63255. [PMID: 35129167 PMCID: PMC8875367 DOI: 10.3791/63255] [Citation(s) in RCA: 2] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 06/13/2024] Open
Abstract
Pathogen tropism and disease tropism refer to the tissue locations selectively colonized or damaged by pathogens, leading to localized disease symptoms. Human-infective trypanosomatid parasites include Trypanosoma cruzi, the causative agent of Chagas disease; Trypanosoma brucei, the causative agent of sleeping sickness; and Leishmania species, causative agents of leishmaniasis. Jointly, they affect 20 million people across the globe. These parasites show specific tropism: heart, esophagus, colon for T. cruzi, adipose tissue, pancreas, skin, circulatory system and central nervous system for T. brucei, skin for dermotropic Leishmania strains, and liver, spleen, and bone marrow for viscerotropic Leishmania strains. A spatial perspective is therefore essential to understand trypanosomatid disease pathogenesis. Chemical cartography generates 3D visualizations of small molecule abundance generated via liquid chromatography-mass spectrometry, in comparison to microbiological and immunological parameters. This protocol demonstrates how chemical cartography can be applied to study pathogenic processes during trypanosomatid infection, beginning from systematic tissue sampling and metabolite extraction, followed by liquid chromatography-tandem mass spectrometry data acquisition, and concluding with the generation of 3D maps of metabolite distribution. This method can be used for multiple research questions, such as nutrient requirements for tissue colonization by T. cruzi, T. brucei, or Leishmania, immunometabolism at sites of infection, and the relationship between local tissue metabolic perturbation and clinical disease symptoms, leading to comprehensive insight into trypanosomatid disease pathogenesis.
Collapse
Affiliation(s)
- Danya A Dean
- Department of Chemistry and Biochemistry, University of Oklahoma, Norman; Laboratories of Molecular Anthropology and Microbiome Research, University of Oklahoma, Norman
| | - Jacob J Haffner
- Laboratories of Molecular Anthropology and Microbiome Research, University of Oklahoma, Norman; Department of Anthropology, University of Oklahoma, Norman
| | | | - Laura-Isobel McCall
- Department of Chemistry and Biochemistry, University of Oklahoma, Norman; Laboratories of Molecular Anthropology and Microbiome Research, University of Oklahoma, Norman; Department of Microbiology and Plant Biology, University of Oklahoma, Norman;
| |
Collapse
|
6
|
Reddy MK, Bhajammanavar V, Baidya M. Annulation Cascade of Sulfamate-Derived Cyclic Imines with Glycine Aldimino Esters: Synthesis of 1,3-Benzoxazepine Scaffolds. Org Lett 2021; 23:3868-3872. [PMID: 33956452 DOI: 10.1021/acs.orglett.1c01001] [Citation(s) in RCA: 3] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/30/2022]
Abstract
An efficient (3 + 2) cycloaddition triggered annulation is reported to access 1,3-benzoxazepine frameworks. With amine base, sulfamate-derived cyclic imines readily react with glycine aldimino esters to furnish benzo-fused seven-membered heterocyclic products in good yields. The cascade reaction involves the formation of one C-C, one C-N, and one C-O bond along with the cleavage of two C-N bonds and one S-O bond. The synthesis of o-tyrosine analogues has also been accomplished from annulation products.
Collapse
Affiliation(s)
- Mallu Kesava Reddy
- Department of Chemistry, Indian Institute of Technology Madras, Chennai 600 036, Tamil Nadu, India
| | - Vinod Bhajammanavar
- Department of Chemistry, Indian Institute of Technology Madras, Chennai 600 036, Tamil Nadu, India
| | - Mahiuddin Baidya
- Department of Chemistry, Indian Institute of Technology Madras, Chennai 600 036, Tamil Nadu, India
| |
Collapse
|
7
|
Zhang C, Zhao H, Li Z, Liang Z, Qi S, Cai M, Zhang S, Jia X, Zhang G, Hu ML. Rapid access to 3-aminoindazoles from nitriles with hydrazines: a strategy to overcome the basicity barrier imparted by hydrazines. Chem Commun (Camb) 2020; 56:9521-9524. [PMID: 32686796 DOI: 10.1039/d0cc03789c] [Citation(s) in RCA: 11] [Impact Index Per Article: 2.8] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/21/2022]
Abstract
A practical and efficient base mediated synthesis of free 3-aminoindazoles has been developed from the reaction of nitriles with hydrazines, which successfully overcomes the difficulty of using aromatic hydrazines as substrates and allows for the synthesis of a wide range of N-aryl substituted free 3-aminoindazoles in moderate to excellent yields under mild conditions in one-pot. This finding provides a rapid and useful strategy for the synthesis of various functionalized 3-aminoindazole derivatives.
Collapse
Affiliation(s)
- Chunyan Zhang
- Key Laboratory of Sensor Analysis of Tumor Marker, Ministry of Education, Shandong Key Laboratory of Biochemical Analysis, Key Laboratory of Analytical Chemistry for Life Science in Universities of Shandong, College of Chemistry and Molecular Engineering, Qingdao University of Science and Technology, Qingdao 266042, P. R. China.
| | - Haowen Zhao
- Key Laboratory of Sensor Analysis of Tumor Marker, Ministry of Education, Shandong Key Laboratory of Biochemical Analysis, Key Laboratory of Analytical Chemistry for Life Science in Universities of Shandong, College of Chemistry and Molecular Engineering, Qingdao University of Science and Technology, Qingdao 266042, P. R. China.
| | - Zehua Li
- Key Laboratory of Sensor Analysis of Tumor Marker, Ministry of Education, Shandong Key Laboratory of Biochemical Analysis, Key Laboratory of Analytical Chemistry for Life Science in Universities of Shandong, College of Chemistry and Molecular Engineering, Qingdao University of Science and Technology, Qingdao 266042, P. R. China.
| | - Zuyu Liang
- Key Laboratory of Sensor Analysis of Tumor Marker, Ministry of Education, Shandong Key Laboratory of Biochemical Analysis, Key Laboratory of Analytical Chemistry for Life Science in Universities of Shandong, College of Chemistry and Molecular Engineering, Qingdao University of Science and Technology, Qingdao 266042, P. R. China.
| | - Shuo Qi
- Key Laboratory of Sensor Analysis of Tumor Marker, Ministry of Education, Shandong Key Laboratory of Biochemical Analysis, Key Laboratory of Analytical Chemistry for Life Science in Universities of Shandong, College of Chemistry and Molecular Engineering, Qingdao University of Science and Technology, Qingdao 266042, P. R. China.
| | - Mingyu Cai
- Key Laboratory of Sensor Analysis of Tumor Marker, Ministry of Education, Shandong Key Laboratory of Biochemical Analysis, Key Laboratory of Analytical Chemistry for Life Science in Universities of Shandong, College of Chemistry and Molecular Engineering, Qingdao University of Science and Technology, Qingdao 266042, P. R. China.
| | - Sheng Zhang
- Key Laboratory of Sensor Analysis of Tumor Marker, Ministry of Education, Shandong Key Laboratory of Biochemical Analysis, Key Laboratory of Analytical Chemistry for Life Science in Universities of Shandong, College of Chemistry and Molecular Engineering, Qingdao University of Science and Technology, Qingdao 266042, P. R. China.
| | - Xiaofei Jia
- Key Laboratory of Sensor Analysis of Tumor Marker, Ministry of Education, Shandong Key Laboratory of Biochemical Analysis, Key Laboratory of Analytical Chemistry for Life Science in Universities of Shandong, College of Chemistry and Molecular Engineering, Qingdao University of Science and Technology, Qingdao 266042, P. R. China.
| | - Guoying Zhang
- Key Laboratory of Sensor Analysis of Tumor Marker, Ministry of Education, Shandong Key Laboratory of Biochemical Analysis, Key Laboratory of Analytical Chemistry for Life Science in Universities of Shandong, College of Chemistry and Molecular Engineering, Qingdao University of Science and Technology, Qingdao 266042, P. R. China.
| | - Mao-Lin Hu
- College of Chemistry and Materials Engineering, Wenzhou University, Wenzhou 325035, P. R. China.
| |
Collapse
|
8
|
Kumar A, Sindhu J, Kumar P. In-silico identification of fingerprint of pyrazolyl sulfonamide responsible for inhibition of N-myristoyltransferase using Monte Carlo method with index of ideality of correlation. J Biomol Struct Dyn 2020; 39:5014-5025. [DOI: 10.1080/07391102.2020.1784286] [Citation(s) in RCA: 4] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/20/2022]
Affiliation(s)
- Ashwani Kumar
- Department of Pharmaceutical Sciences, Guru Jambeshwar University of Science and Technology, Hisar, Haryana, India
| | - Jayant Sindhu
- Department of Chemistry, COBS&H, CCS Haryana Agricultural University, Hisar, Haryana, India
| | - Parvin Kumar
- Department of Chemistry, Kurukshetra University, Kurukshetra, Haryana, India
| |
Collapse
|
9
|
High-Throughput Screening of the ReFRAME Library Identifies Potential Drug Repurposing Candidates for Trypanosoma cruzi. Microorganisms 2020; 8:microorganisms8040472. [PMID: 32224991 PMCID: PMC7232187 DOI: 10.3390/microorganisms8040472] [Citation(s) in RCA: 9] [Impact Index Per Article: 2.3] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/19/2020] [Revised: 03/21/2020] [Accepted: 03/23/2020] [Indexed: 12/27/2022] Open
Abstract
Chagas disease, caused by the kinetoplastid parasite Trypanosoma cruzi, affects between 6 and 7 million people worldwide, with an estimated 300,000 to 1 million of these cases in the United States. In the chronic phase of infection, T. cruzi can cause severe gastrointestinal and cardiac disease, which can be fatal. Currently, only benznidazole is clinically approved by the FDA for pediatric use to treat this infection in the USA. Toxicity associated with this compound has driven the search for new anti-Chagas agents. Drug repurposing is a particularly attractive strategy for neglected diseases, as pharmacological parameters and toxicity are already known for these compounds, reducing costs and saving time in the drug development pipeline. Here, we screened 7680 compounds from the Repurposing, Focused Rescue, and Accelerated Medchem (ReFRAME) library, a collection of drugs or compounds with confirmed clinical safety, against T. cruzi. We identified seven compounds of interest with potent in vitro activity against the parasite with a therapeutic index of 10 or greater, including the previously unreported activity of the antiherpetic compound 348U87. These results provide the framework for further development of new T. cruzi leads that can potentially move quickly to the clinic.
Collapse
|